Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
M
235980
vs
K
KOSPI 200
Over the past 12 months, MedPacto Inc has underperformed KOSPI 200, delivering a return of -32% compared to KOSPI 200's +62% growth.
Stocks Performance
235980 vs KOSPI 200
Performance Gap
235980 vs KOSPI 200
Performance By Year
235980 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
MedPacto Inc
Glance View
MedPacto Inc is a South Korean biopharmaceutical company that develops drug candidates for cancer and other serious diseases. Its work is centered on researching new medicines, testing them in preclinical and clinical studies, and turning promising molecules into treatments that can be licensed or sold if they succeed. The company makes money mainly by advancing its drug pipeline and, in some cases, by partnering with larger pharmaceutical companies that may pay for development rights, milestones, or future sales participation. Its main customers are not ordinary consumers but drug developers, hospitals, and ultimately patients who would use the medicines if they reach the market. What makes MedPacto different is that it sits early in the drug value chain, where the main asset is intellectual property rather than a finished product. That means its business depends on scientific results, regulatory approval, and partnerships, which is very different from a typical manufacturer or retailer.